Lingamneni Anila

SEC source: 0001127602-24-020383 · form4.xml · nonDerivative · entry 2

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,331

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated March 13, 2024 (fully executed as of March 13, 2024).

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-24-020383 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,410

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated March 13, 2024 (fully executed as of March 13, 2024).

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-24-016816 · form4.xml · nonDerivative · entry 2

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,546

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016816 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,825

F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016171 · form4.xml · derivative · entry 3

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,461

Underlying: Common Stock · 7,461 shares

Expires 2031-05-17

F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-24-016171 · form4.xml · nonDerivative · entry 2

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,685

F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-016171 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,291

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-015834 · form4.xml · nonDerivative · entry 2

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,640

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-015834 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,958

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-014594 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,295

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 2, 2023 (fully executed as of June 5, 2023).

F2 · balance_after: This number includes unvested restricted stock units previously reported as well as 289 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2024.

SEC source: 0001127602-24-013101 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,311

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-23-024071 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,495

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 2, 2023 (fully executed as of June 5, 2023).

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-23-017355 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,800

F1 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-23-016314 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,104

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-23-015939 · form4.xml · nonDerivative · entry 2

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,489

F4 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.

F3 · balance_after: This number includes unvested RSUs previously reported as well as 297 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 28, 2023.

SEC source: 0001127602-23-015939 · form4.xml · derivative · entry 3

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,602

Underlying: Common Stock · 7,602 shares

Expires 2030-05-15

F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-23-015939 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,807

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported as well as 297 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 28, 2023.

SEC source: 0001127602-23-013161 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,146

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-22-015366 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,322

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-22-014984 · form4.xml · derivative · entry 2

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,148

Underlying: Common Stock · 10,148 shares

Expires 2029-05-16

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-22-014984 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,706

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported as well as 353 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 29, 2022.

SEC source: 0001127602-22-012143 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,013

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-21-017682 · form4.xml · nonDerivative · entry 3

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,202

F5 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · balance_after: This number includes unvested RSUs previously reported as well as 245 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2021.

SEC source: 0001127602-21-017682 · form4.xml · derivative · entry 4

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,564

Underlying: Common Stock · 9,564 shares

Expires 2028-05-18

F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-21-017682 · form4.xml · nonDerivative · entry 2

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,294

F4 · kind: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant.

F4 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported as well as 245 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2021.

SEC source: 0001127602-21-017682 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,224

F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported as well as 245 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2021.

SEC source: 0001127602-21-014117 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,444

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs and 224 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 30, 2020.

SEC source: 0001127602-20-017268 · form4.xml · derivative · entry 2

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,092

Underlying: Common Stock · 4,092 shares

Expires 2027-05-18

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-20-017268 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,390

F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-20-014068 · form4.xml · derivative · entry 2

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,509

Underlying: Common Stock · 7,509 shares

Expires 2027-04-15

F3 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-20-014068 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,181

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.